11 unchanged sentences
Purchased Under
−Removed: April 1, 2025 - April 30, 2025 1,102 (1)
+Added: July 1, 2025 - July 31, 2025 1,043 (1)
— $2,896,110,760
−Removed: May 1, 2025 - May 31, 2025 995 (1)
+Added: August 1, 2025 - August 31, 2025 989 (1)
— $2,896,110,760
−Removed: June 1, 2025 - June 30, 2025 1,081 (1)
+Added: September 1, 2025 - September 30, 2025 994 (1)
— $2,896,110,760
1 unchanged sentence
— $2,896,110,760
−Removed: In addition to AbbVie shares repurchased on the open market under a publicly announced program, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 1,102 in April;
−Removed: and 1,081 in June.
+Added: In addition to AbbVie shares repurchased on the open market under a publicly announced program, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 1,043 in July;
+Added: 989 in August;
+Added: and 994 in September.
These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.
(c) Director and Officer Trading Arrangements
−Removed: During the three months ended June 30, 2025, no director or officer of the company adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended September 30, 2025, no director or officer of the company adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
2025 Form 10-Q |
1 unchanged sentence
Exhibit Description
+Added: AbbVie Deferred Compensation Plan, as amended and restated.*
+Added: AbbVie Supplemental Pension Plan, as amended and restated.*
Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
5 unchanged sentences
101 The following financial statements and notes from the AbbVie Inc.
−Removed: Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed on August 4, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed on November 4, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) Condensed Consolidated Statements of Earnings;
12 unchanged sentences
Chief Financial Officer (Principal Financial Officer)
−Removed: August 4, 2025
+Added: November 4, 2025
2025 Form 10-Q |
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.